Evidence map›Paper›PMID 30231498›Full record

ArticleToxins2018

A Critical Role for HlgA in

Arundhathi Venkatasubramaniam, Tulasikumari Kanipakala, Nader Ganjbaksh, Rana Mehr, Ipsita Mukherjee, Subramaniam Krishnan, Taeok Bae, M Javad Aman, Rajan P Adhikari

Open access · goldAbstract read
In one paragraph

Article in Toxins, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Cucurbitacin B mitigatesJournal of pharmaceutical analysis · 2026
    Article
  2. α-hemolysin polymorphisms in methicillin-resistantbioRxiv : the preprint server for biology · 2025
    Article
  3. Article
  4. Review
  5. Activation of themBio · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Leukotoxins.Toxins · 2020
    Article
  18. Review
  19. Article
  20. Bacterial outer membrane vesicles engineered with lipidated antigens as a platform forProceedings of the National Academy of Sciences of the United States of America · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Arundhathi VenkatasubramaniamIntegrated Biotherapeutics Inc., Rockville, MD 20850, USA. Arundhathi@integratedbiotherapeutics.com.
Tulasikumari KanipakalaIntegrated Biotherapeutics Inc., Rockville, MD 20850, USA. Tula@integratedbiotherapeutics.com.
Nader GanjbakshIntegrated Biotherapeutics Inc., Rockville, MD 20850, USA. Nader@integratedbiotherapeutics.com.
Rana MehrIntegrated Biotherapeutics Inc., Rockville, MD 20850, USA. ranamehr@gmail.com.
Ipsita MukherjeeIntegrated Biotherapeutics Inc., Rockville, MD 20850, USA. imukher@integratedbiotherapeutics.com.
Subramaniam KrishnanIntegrated Biotherapeutics Inc., Rockville, MD 20850, USA. subramaniamkrish@gmail.com.
Taeok BaeDepartment of Microbiology and Immunology, Indiana University School of Medicine-Northwest, Gary, IN 46408, USA. tbae@iun.edu.
M Javad AmanIntegrated Biotherapeutics Inc., Rockville, MD 20850, USA. javad@integratedbiotherapeutics.com.
Rajan P AdhikariIntegrated Biotherapeutics Inc., Rockville, MD 20850, USA. rajan@integratedbiotherapeutics.com.
Integrated BioTherapeutics (United States) · USIndiana University School of Medicine

Funding

Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus diseaseR01AI111205 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI M Javad Aman · 2015 to 2026
$6.9M
In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureusR43AI106162 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI ADHIKARI, RAJAN P · 2014 to 2015
$600k
A novel Structure Based Vaccine for staphylococcal alpha hemolysinR43AI098232 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI ADHIKARI, RAJAN P · 2012 to 2013
$591k
NIAID NIH HHS R01 AI111205NIAID NIH HHS R43 AI098232NIAID NIH HHS R43 AI106162
6 · The paper itself

Abstract

Cytolytic pore-forming toxins including alpha hemolysin (Hla) and bicomponent leukotoxins play an important role in the pathogenesis of

Indexed as

AnimalsBacterial ProteinsBacterial ToxinsErythrocytesHemolysin ProteinsHemolysisHumansMicePneumoniaProtein KinasesStaphylococcus aureusVirulenceBacterial ProteinsBacterial Toxinsgamma-hemolysin, Staphylococcus aureusHemolysin ProteinsProtein KinasesSaeS protein, Staphylococcus aureusagrhlahlgAleukotoxinsNewmanSaeSS. aureus

Identifiers

PMID30231498
PMCPMC6162840
OpenAlexW2889723928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.